Stephens Investment Management Group LLC Buys 98,460 Shares of Repligen Corporation $RGEN

Stephens Investment Management Group LLC boosted its stake in Repligen Corporation (NASDAQ:RGEN) by 15.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 755,571 shares of the biotechnology company’s stock after purchasing an additional 98,460 shares during the quarter. Repligen comprises approximately 1.2% of Stephens Investment Management Group LLC’s portfolio, making the stock its 15th biggest holding. Stephens Investment Management Group LLC owned approximately 1.34% of Repligen worth $89,021,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Iron Triangle Partners LP purchased a new position in Repligen in the third quarter worth $36,091,000. Hudson Bay Capital Management LP purchased a new stake in Repligen during the third quarter valued at about $2,807,000. Massachusetts Financial Services Co. MA purchased a new stake in Repligen during the fourth quarter valued at about $199,176,000. Cinctive Capital Management LP bought a new stake in Repligen during the third quarter worth about $3,398,000. Finally, Schroder Investment Management Group lifted its stake in Repligen by 123.2% during the third quarter. Schroder Investment Management Group now owns 460,609 shares of the biotechnology company’s stock worth $61,570,000 after purchasing an additional 254,212 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of research reports. Jefferies Financial Group reiterated a “hold” rating and issued a $142.00 price objective on shares of Repligen in a report on Tuesday, May 5th. JPMorgan Chase & Co. dropped their target price on Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. HC Wainwright upped their target price on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Roth Mkm initiated coverage on Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 target price for the company. Finally, Canaccord Genuity Group reduced their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a research report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $164.64.

Insiders Place Their Bets

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.60% of the company’s stock.

Repligen Price Performance

RGEN opened at $142.40 on Friday. The company has a market cap of $8.03 billion, a P/E ratio of 158.22, a P/E/G ratio of 2.74 and a beta of 1.06. The business’s 50-day moving average price is $123.84 and its 200-day moving average price is $134.79. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company had revenue of $194.25 million during the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the previous year, the company posted $0.39 EPS. Repligen’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, equities analysts expect that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.